BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population Combining Targeted and Unsupervised Biological Measurements With Non-Invasive Imaging Modalities to Identify Biomarkers That Predict Near Term (1-3-years) Outcomes
Sponsor: Abbott
Listed as NCT00738725, this observational or N/A phase trial focuses on Atherosclerotic Disease and Heart Disease and remains completed. Sponsored by Abbott, it has been updated 11 times since 2008, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2022 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Jun 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- AstraZeneca
- BG Medicine, Inc
- Merck Sharp & Dohme LLC
- Philips Medical Systems
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .